

George Pentheroudakis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5569605/publications.pdf>

Version: 2024-02-01

43
papers

1,046
citations

567281

15
h-index

434195

31
g-index

45
all docs

45
docs citations

45
times ranked

2028
citing authors

#	ARTICLE	IF	CITATIONS
1	Cancer and pregnancy: Poena magna, not anymore. <i>European Journal of Cancer</i> , 2006, 42, 126-140.	2.8	229
2	Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 108, 164-174.	4.4	134
3	Current and future biomarkers in colorectal cancer. <i>Annals of Gastroenterology</i> , 2017, 30, 613-621.	0.6	88
4	ESMO Management and treatment adapted recommendations in the COVID-19 era: Pancreatic Cancer. <i>ESMO Open</i> , 2020, 5, e000804.	4.5	61
5	ESMO management and treatment adapted recommendations in the COVID-19 era: colorectal cancer. <i>ESMO Open</i> , 2020, 5, e000826.	4.5	60
6	A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial Experience. <i>Oncologist</i> , 2021, 26, e769-e779.	3.7	48
7	Non-epithelial Ovarian Cancer: Elucidating Uncommon Gynaecological Malignancies. <i>Anticancer Research</i> , 2016, 36, 5031-5042.	1.1	47
8	Cancer of Unknown Primary origin in the genomic era: Elucidating the dark box of cancer. <i>Cancer Treatment Reviews</i> , 2015, 41, 598-604.	7.7	46
9	Novel microRNA-based assay demonstrates 92% agreement with diagnosis based on clinicopathologic and management data in a cohort of patients with carcinoma of unknown primary. <i>Molecular Cancer</i> , 2013, 12, 57.	19.2	43
10	Prognostic implications of mismatch repair deficiency in patients with nonmetastatic colorectal and endometrial cancer. <i>ESMO Open</i> , 2019, 4, e000474.	4.5	34
11	Global microRNA profiling in favorable prognosis subgroups of cancer of unknown primary (CUP) demonstrates no significant expression differences with metastases of matched known primary tumors. <i>Clinical and Experimental Metastasis</i> , 2013, 30, 431-439.	3.3	23
12	Primary Pulmonary Malignant Melanoma: Report of an Important Entity and Literature Review. <i>Case Reports in Oncological Medicine</i> , 2017, 2017, 1-9.	0.3	22
13	Nivolumab-induced hypothyroidism and selective pituitary insufficiency in a patient with lung adenocarcinoma: a case report and review of the literature. <i>ESMO Open</i> , 2017, 2, e000217.	4.5	20
14	Prognostic impact of stromal and intratumoral CD3, CD8 and FOXP3 in adjuvantly treated breast cancer: do they add information over stromal tumor-infiltrating lymphocyte density?. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1549-1564.	4.2	19
15	Angiogenic and Antiangiogenic VEGFA Splice Variants in Colorectal Cancer: Prospective Retrospective Cohort Study in Patients Treated With Irinotecan-Based Chemotherapy and Bevacizumab. <i>Clinical Colorectal Cancer</i> , 2019, 18, e370-e384.	2.3	18
16	Pancreatic resection for renal cell carcinoma metastasis: An exceptionally rare coexistence. <i>International Journal of Surgery Case Reports</i> , 2016, 27, 198-201.	0.6	15
17	AMALTHEA: Prospective, Single-Arm Study of the Hellenic Cooperative Oncology Group (HeCOG) Evaluating Efficacy and Safety of First-Line FOLFIRI+ Aflibercept for 6 Months Followed by Aflibercept Maintenance in Patients With Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2018, 17, e631-e637.	2.3	12
18	A case report of psoriasis flare following immunotherapy: Report of an important entity and literature review. <i>SAGE Open Medical Case Reports</i> , 2020, 8, 2050313X1989770.	0.3	12

#	ARTICLE	IF	CITATIONS
19	Postoperative chemotherapy with single-agent fluoropyrimidines after resection of colorectal cancer liver metastases: a meta-analysis of randomised trials. <i>ESMO Open</i> , 2018, 3, e000343.	4.5	11
20	Old drug, new clinical use, no manâ€™s land for the indication: an awareness call from European experts. <i>ESMO Open</i> , 2020, 5, e000615.	4.5	10
21	Genetic mapping of pancreatic cancer by targeted next-generation sequencing in a cohort of patients managed with nab-paclitaxel-based chemotherapy or agents targeting the EGFR axis: a retrospective analysis of the Hellenic Cooperative Oncology Group (HeCOG). <i>ESMO Open</i> , 2019, 4, e000525.	4.5	8
22	Predictive biomarkers to chemotherapy in patients with advanced melanoma receiving the combination of cisplatin–vinblastine–temozolomide (PVT) as first-line treatment: a study of the Hellenic Cooperative Oncology Group (HECOG). <i>Anticancer Research</i> , 2015, 35, 1105-13.	1.1	8
23	Characterization and prevalence of two novel CHEK2 large deletions in Greek breast cancer patients. <i>Journal of Human Genetics</i> , 2018, 63, 877-886.	2.3	7
24	First Line Gemcitabine/Pazopanib in Locally Advanced and/or Metastatic Biliary Tract Carcinoma. A Hellenic Cooperative Oncology Group Phase II Study. <i>Anticancer Research</i> , 2020, 40, 929-938.	1.1	7
25	Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital. <i>JCO Clinical Cancer Informatics</i> , 2022, , .	2.1	7
26	How I treat cancers of unknown primary. <i>ESMO Open</i> , 2019, 4, e000502.	4.5	6
27	Genotype-phenotype associations in colorectal adenocarcinomas and their matched metastases. <i>Human Pathology</i> , 2021, 107, 104-116.	2.0	6
28	AGAPP: efficacy of first-line cisplatin, 5-fluorouracil with afatinib in inoperable gastric and gastroesophageal junction carcinomas. A Hellenic Cooperative Oncology Group study. <i>Acta Oncol</i> , 2021, 60, 785-793.	1.8	5
29	Prognostic significance of WNT and hedgehog pathway activation markers in cancer of unknown primary. <i>European Journal of Clinical Investigation</i> , 2015, 45, 1145-1152.	3.4	4
30	Cancer of unknown primary: time to put the pieces of the puzzle together?. <i>Lancet Oncology</i> , The, 2016, 17, 1339-1340.	10.7	4
31	Update on clinical research and state of the art management of patients with advanced sarcomas and GIST. <i>ESMO Open</i> , 2016, 1, e000065.	4.5	4
32	Molecular findings reveal possible resistance mechanisms in a patient with ALK-rearranged lung cancer: a case report and literature review. <i>ESMO Open</i> , 2019, 4, e000561.	4.5	4
33	Acquired Hemophilia in an Elderly Patient with Carcinoma of the Ampulla of Vater. <i>Case Reports in Oncology</i> , 2020, 13, 1-6.	0.7	4
34	Androgen Receptor and PIM1 Expression in Tumor Tissue of Patients With Triple-negative Breast Cancer. <i>Cancer Genomics and Proteomics</i> , 2021, 18, 147-156.	2.0	4
35	Relapsing Episodes of Loss of Consciousness in a Patient With Hepatocellular Carcinoma. <i>World Journal of Oncology</i> , 2014, 5, 214-219.	1.5	4
36	Cyclin D1 differential activation and its prognostic impact in patients with advanced breast cancer treated with trastuzumab. <i>ESMO Open</i> , 2019, 4, e000441.	4.5	3

#	ARTICLE	IF	CITATIONS
37	Efficacy and Safety of First-Line Everolimus Therapy Alone or in Combination with Octreotide in Gastroenteropancreatic Neuroendocrine Tumors. A Hellenic Cooperative Oncology Group (HeCOG) Study. <i>Biology</i> , 2020, 9, 51.	2.8	2
38	Tumor Mutational Patterns and Infiltrating Lymphocyte Density in Young and Elderly Patients With Breast Cancer. <i>Cancer Genomics and Proteomics</i> , 2020, 17, 181-193.	2.0	2
39	Genotyping data of routinely processed matched primary/metastatic tumor samples. <i>Data in Brief</i> , 2021, 34, 106646.	1.0	2
40	Mismatch repair deficiency/microsatellite instability testing as predictive immunotherapy biomarkers—possible diagnostic missteps trusting a single method. <i>Annals of Translational Medicine</i> , 2019, 7, S329-S329.	1.7	1
41	mRNA expression of specific HER ligands and their association with clinical outcome in patients with metastatic breast cancer treated with trastuzumab. <i>Oncology Letters</i> , 2021, 23, 23.	1.8	1
42	Clinical Significance of Major Angiogenesis-Related Effectors in Patients with Metastatic Breast Cancer Treated with Trastuzumab-based Regimens. <i>Cancer Research and Treatment</i> , 2021, , .	3.0	1
43	TAILORing targeted therapies to the right patient at the right time: how close are we?. <i>Annals of Translational Medicine</i> , 2018, 6, S87-S87.	1.7	0